Burden of Children Hospitalized With Pertussis in Canada in the Acellular Pertussis Vaccine Era, 1999-2015.


Journal

Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049

Informations de publication

Date de publication:
30 Apr 2020
Historique:
received: 29 08 2018
pubmed: 12 12 2018
medline: 15 12 2020
entrez: 12 12 2018
Statut: ppublish

Résumé

Recent increases in pertussis morbidity and mortality rates among young infants have led to a recommendation in some countries for vaccination against pertussis during pregnancy. Having data on the burden of pediatric pertussis in a large population over time is important for establishing the true burden of disease in the acellular pertussis (aP) vaccine era. Here, we describe age-specific epidemiology and morbidity and mortality rates in children hospitalized with pertussis over 17 years across Canada in the aP vaccine era. Patients aged ≤16 years who were admitted to 1 of 12 pediatric tertiary-care hospitals across Canada between 1999 and 2015 with confirmed (laboratory-confirmed or epidemiologically linked) or probable (clinically diagnosed) pertussis were included. Overall, 1402 patients with pertussis were included. Infants aged <2 months had the highest mean annual incidences of pertussis hospitalization and intensive care unit (ICU) admission (116.40 [95% confidence interval (CI), 85.32-147.49] and 33.48 [95% CI, 26.35-40.62] per 100 000 population, respectively). The overall proportion of children who required ICU admission was 25.46%, and the proportion was highest in infants aged <2 months (37.90%). Over the span of this study, 21 deaths occurred. Age of <16 weeks, prematurity, encephalopathy, and a confirmed pertussis diagnosis were independent risk factors for ICU admission. Age of <4 weeks, prematurity, and female sex were independent risk factors for death. In the aP vaccine era, endemic pertussis still contributes considerably to childhood morbidity and death, particularly in infants aged <2 months. Vaccination against pertussis during pregnancy has the potential to reduce this disease burden.

Sections du résumé

BACKGROUND BACKGROUND
Recent increases in pertussis morbidity and mortality rates among young infants have led to a recommendation in some countries for vaccination against pertussis during pregnancy. Having data on the burden of pediatric pertussis in a large population over time is important for establishing the true burden of disease in the acellular pertussis (aP) vaccine era. Here, we describe age-specific epidemiology and morbidity and mortality rates in children hospitalized with pertussis over 17 years across Canada in the aP vaccine era.
METHODS METHODS
Patients aged ≤16 years who were admitted to 1 of 12 pediatric tertiary-care hospitals across Canada between 1999 and 2015 with confirmed (laboratory-confirmed or epidemiologically linked) or probable (clinically diagnosed) pertussis were included.
RESULTS RESULTS
Overall, 1402 patients with pertussis were included. Infants aged <2 months had the highest mean annual incidences of pertussis hospitalization and intensive care unit (ICU) admission (116.40 [95% confidence interval (CI), 85.32-147.49] and 33.48 [95% CI, 26.35-40.62] per 100 000 population, respectively). The overall proportion of children who required ICU admission was 25.46%, and the proportion was highest in infants aged <2 months (37.90%). Over the span of this study, 21 deaths occurred. Age of <16 weeks, prematurity, encephalopathy, and a confirmed pertussis diagnosis were independent risk factors for ICU admission. Age of <4 weeks, prematurity, and female sex were independent risk factors for death.
CONCLUSIONS CONCLUSIONS
In the aP vaccine era, endemic pertussis still contributes considerably to childhood morbidity and death, particularly in infants aged <2 months. Vaccination against pertussis during pregnancy has the potential to reduce this disease burden.

Identifiants

pubmed: 30535079
pii: 5236699
doi: 10.1093/jpids/piy128
pmc: PMC7192396
doi:

Substances chimiques

Diphtheria-Tetanus-acellular Pertussis Vaccines 0
Pertussis Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118-127

Investigateurs

N Bridger (N)
R Morris (R)
K Top (K)
S Halperin (S)
P Déry (P)
R Thibeault (R)
D Moore (D)
M A Lefebvre (MA)
M Lebel (M)
N Le Saux (N)
D Tran (D)
L Ford-Jones (L)
S Morris (S)
J Embree (J)
B Law (B)
B Tan (B)
A McConnell (A)
T Jadavji (T)
R Chawla (R)
O Vanderkooi (O)
J Kellner (J)
W Vaudry (W)
D Scheifele (D)
J Bettinger (J)
M Sadarangani (M)
L Sauvé (L)

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society.

Références

Lancet Infect Dis. 2017 Sep;17(9):974-980
pubmed: 28623146
MMWR Morb Mortal Wkly Rep. 2014 Dec 5;63(48):1129-32
pubmed: 25474033
J Pediatr. 2010 Mar;156(3):498-500
pubmed: 20056236
Lancet. 2014 Oct 25;384(9953):1521-8
pubmed: 25037990
Can Commun Dis Rep. 2018 Mar 01;44(3-4):91-94
pubmed: 31007617
J Pediatr. 2003 Nov;143(5):576-81
pubmed: 14615725
Pediatr Infect Dis J. 2005 Sep;24(9):761-5
pubmed: 16148840
Pediatr Infect Dis J. 2009 Mar;28(3):194-8
pubmed: 19209089
Pediatrics. 1996 May;97(5):607-12
pubmed: 8628595
MMWR Morb Mortal Wkly Rep. 2012 Jul 20;61(28):517-22
pubmed: 22810264
J Paediatr Child Health. 2008 Apr;44(4):161-5
pubmed: 18377367
Pediatr Infect Dis J. 2005 May;24(5 Suppl):S87-92
pubmed: 15876934
Pediatr Infect Dis J. 2018 Mar;37(3):202-205
pubmed: 28737623
BMJ Open. 2016 Apr 06;6(4):e010386
pubmed: 27053270
Pediatr Infect Dis J. 2004 Mar;23(3):246-52
pubmed: 15014301
Clin Infect Dis. 1999 Jun;28(6):1238-43
pubmed: 10451159
Epidemiol Infect. 1999 Dec;123(3):403-11
pubmed: 10694150
Clin Infect Dis. 2017 Jan 1;64(1):3-8
pubmed: 27624955
J Pediatric Infect Dis Soc. 2013 Mar;2(1):1-6
pubmed: 26619437
Pediatr Crit Care Med. 2016 Aug;17(8):735-42
pubmed: 27362854
Clin Infect Dis. 2017 Jan 1;64(1):9-14
pubmed: 27624956
Clin Infect Dis. 2015 Oct 1;61(7):1099-106
pubmed: 26082502
J Pediatr. 2012 Dec;161(6):1091-6
pubmed: 22819634
Clin Infect Dis. 2015 Feb 1;60(3):333-7
pubmed: 25332078
Pediatr Infect Dis J. 2005 May;24(5 Suppl):S83-6
pubmed: 15876933
Pediatr Crit Care Med. 2007 May;8(3):207-11
pubmed: 17417115
Pediatr Infect Dis J. 2007 Jan;26(1):31-5
pubmed: 17195702
MMWR Morb Mortal Wkly Rep. 2013 Feb 22;62(7):131-5
pubmed: 23425962

Auteurs

Bahaa Abu-Raya (B)

Vaccine Evaluation Center, BC Children's Hospital, University of British Columbia, Vancouver, Canada.

Julie A Bettinger (JA)

Vaccine Evaluation Center, BC Children's Hospital, University of British Columbia, Vancouver, Canada.

Otto G Vanderkooi (OG)

Departments of Paediatrics, Microbiology, Immunology and Infectious Diseases, Pathology, and Laboratory Medicine, University of Calgary, Canada.
Alberta Children's Hospital Research Institute, Alberta Health Services, Canada.

Wendy Vaudry (W)

Division of Infectious Diseases, Department of Pediatrics, University of Alberta, Stollery Children's Hospital, Edmonton, Canada.

Scott A Halperin (SA)

Canadian Center for Vaccinology, Dalhousie University and the IWK Health Centre and Nova Scotia Health Authority, Halifax, Canada.
Department of Pediatrics, Dalhousie University and the IWK Health Centre and Nova Scotia Health Authority, Halifax, Canada.
Department of Microbiology and Immunology, Dalhousie University and the IWK Health Centre and Nova Scotia Health Authority, Halifax, Canada.

Manish Sadarangani (M)

Vaccine Evaluation Center, BC Children's Hospital, University of British Columbia, Vancouver, Canada.
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH